Want to see ACRS full AI Analyst Report?
ACRS Stock Chart & Stats
$4.25
-$0.03(-1.20%)
At close: 4:00 PM EST
$4.25
-$0.03(-1.20%)
Day’s Range― - ―
52-Week Range$1.46 - $5.85
Previous CloseN/A
Volume227.82K
Average Volume (3M)1.11M
Market Cap
$793.29M
Enterprise Value$379.61
Total Cash (Recent Filing)$105.42M
Total Debt (Recent Filing)$1.99M
Price to Earnings (P/E)―
Beta1.46
Next Earnings
Aug 12, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.56
Shares Outstanding139,663,680
10 Day Avg. Volume1,094,755
30 Day Avg. Volume1,106,653
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)3.58
Price to Sales (P/S)47.18
P/FCF Ratio-7.84
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$10.75Price Target Upside152.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.67
Revenue Forecast (FY)$5.71M
Bulls Say, Bears Say
Bulls Say
High Gross Margins & Low LeverageSustained high gross margins (~76% TTM, ~85% in 2024) combined with minimal debt provide durable operating leverage and financial flexibility. This supports program funding efficiency and preserves gross profit per revenue dollar as clinical programs scale, reducing reliance on borrowed capital.
Advancing Pipeline With Positive Phase 1a DataPositive first-in-human Phase 1a data for ATI-052 materially de-risks that program and suggests a differentiated pharmacokinetic profile enabling infrequent dosing. Durable implications include stronger clinical and commercial potential in large immunology markets and clearer go-to-market positioning for follow-on development.
Access To Capital Via Recent Equity FinancingsDemonstrated ability to raise equity capital provides a durable funding channel to support ongoing clinical development and R&D without materially increasing interest burden. This reduces short-term solvency risk and allows the company to advance multiple programs while pursuing regulatory milestones.
Bears Say
Persistent Cash BurnRun-rate cash burn of roughly -$52M TTM is a durable structural constraint requiring ongoing external funding. Persistent negative operating and free cash flow limit internal reinvestment, increase dependence on equity markets, and raise execution risk if capital access tightens or dilutive financings become constrained.
Small, Volatile Revenue And Deep LossesA small, unstable revenue base means current revenues cannot absorb fixed R&D and G&A, keeping operating losses structurally large. Until the company achieves consistent revenue growth or significantly reduces burn, profitability will remain elusive, hindering long-term self-sufficiency and scaling prospects.
Equity Dilution Risk & Negative ROEFluctuating equity and persistently negative ROE indicate shareholder value erosion from repeated funding rounds. Continued reliance on equity financing to cover burn risks long-term dilution, compresses potential returns, and can weaken investor incentives unless clinical programs deliver clear value inflection points.
Aclaris Therapeutics News
ACRS FAQ
What was Aclaris Therapeutics’s price range in the past 12 months?
Aclaris Therapeutics lowest stock price was $1.46 and its highest was $5.85 in the past 12 months.
What is Aclaris Therapeutics’s market cap?
Aclaris Therapeutics’s market cap is $793.29M.
When is Aclaris Therapeutics’s upcoming earnings report date?
Aclaris Therapeutics’s upcoming earnings report date is Aug 12, 2026 which is in 24 days.
How were Aclaris Therapeutics’s earnings last quarter?
Aclaris Therapeutics released its earnings results on May 12, 2026. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.158 by $0.008.
Is Aclaris Therapeutics overvalued?
According to Wall Street analysts Aclaris Therapeutics’s price is currently Undervalued.
Does Aclaris Therapeutics pay dividends?
Aclaris Therapeutics does not currently pay dividends.
What is Aclaris Therapeutics’s EPS estimate?
Aclaris Therapeutics’s EPS estimate is -0.16.
How many shares outstanding does Aclaris Therapeutics have?
Aclaris Therapeutics has 139,663,680 shares outstanding.
What happened to Aclaris Therapeutics’s price movement after its last earnings report?
Aclaris Therapeutics reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.158. Following the earnings report the stock price went down -1.414%.
Which hedge fund is a major shareholder of Aclaris Therapeutics?
Currently, no hedge funds are holding shares in ACRS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aclaris Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.75 (152.94% Upside)
$10.75 (152.94% Upside)
Hedge Fund Trend
Increased
By 7.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 2.4%
Last 30 Days ▲ 1.9%
Last 30 Days ▲ 1.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
62.39%
12-Months-Change
Fundamentals
Return on Equity
-55.89%
Trailing 12-Months
Asset Growth
0.32%
Trailing 12-Months
Company Description
Aclaris Therapeutics
Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are divided into two primary divisions: the Therapeutics segment, dedicated to discovering and progressing innovative treatments to address crucial unmet needs in immuno-inflammatory disorders; and the Contract Research segment, which delivers specialized laboratory services. The company's pipeline features several investigational compounds. Among these is Zunsemetinib, an MK2 inhibitor, being developed to treat moderate to severe cases of rheumatoid arthritis, psoriatic arthritis, and hidradenitis suppurativa. Another significant candidate is ATI-1777, a soft JAK 1/3 inhibitor, intended for the management of moderate to severe atopic dermatitis. Additionally, Aclaris is advancing ATI-2138, an ITK/TXK/JAK3 inhibitor, as a potential intervention for T cell-mediated autoimmune diseases; a Gut-Biased Program targeting inflammatory bowel disease; and ATI-2231, an MK2 inhibitor, for the treatment of pancreatic and metastatic breast cancer. Established in 2012, Aclaris Therapeutics, Inc. has its corporate headquarters situated in Wayne, Pennsylvania.
ACRS Stock 12 Month Forecast
Average Price Target
$10.75
▲(152.94% Upside)
Technical Analysis
Ownership Overview
12.39% Insiders
7.33% Mutual Funds
1.08% Other Institutional Investors
65.37% Public Companies and Individual Investors